Top Story

AHA and ADA: CV risk assessment, monitoring essential for patients with type 1 diabetes

August 21, 2014

A greater understanding of the pathophysiology, risk prediction and treatment of CVD in patients with type 1 diabetes is essential to minimize the impact of these interrelated conditions, according to a new scientific statement from the American Heart Association and American Diabetes Association.

“CVD is a long-term complication of type 1 diabetes that is a major concern for patients and health care providers. … Despite the known higher risk of CVD in individuals with type 1 diabetes mellitus, the pathophysiology underlying the relationship between CV events, CVD risk factors and type 1 diabetes is not well understood,” the authors wrote in Diabetes Care.

figure FDA News

FDA opens dialogue on interim results of CV safety in diabetes drug trials

August 12, 2014
The FDA has launched a dialogue on how to handle confidentiality of the interim results for cardiovascular outcomes in diabetes treatment trials while new trials are…
In the Journals

Knowing modifiable risk factors may reduce CV death in type 2 diabetes

July 9, 2014
Determining vascular calcification and modifiable risk factors for heart disease could provide patients with type 2 diabetes the insight needed to take steps toward…
Meeting News Coverage

Higher obesity increases odds for cardiovascular, cancer, diabetes deaths

July 8, 2014
Adults with class III obesity are more likely to die from all causes than those within normal weight range, but particularly from heart disease, cancer and diabetes…
CME

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

2/1/2014
Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »
CME

Individualizing T2DM Treatment: Determining Optimal Pathways that Lead to Achieving Target Goals

This activity is supported by educational grants from Lilly and Novo Nordisk.

10/11/2013
The prevalence of type 2 diabetes mellitus has escalated in recent years and targeting treatmentcontinues to be a…
More »

Filter By:

In the Journals

Hyperglycemia at hospitalization increased risk for future diabetes in MI patients

March 14, 2014
Approximately one in six patients hospitalized for acute MI have hyperglycemia without known diabetes, and these patients are at a 2.5-fold increased…
In the Journals

Cardiac death, MI remain increased in patients with diabetes treated with DES

March 13, 2014
Among patients treated with drug-eluting stents during the DES era, researchers observed a higher rate of death or MI in those with diabetes compared…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

March 12, 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Gestational diabetes may be marker for early atherosclerosis

Cardiology Today, April 2014
History of gestational diabetes appears to be a marker for early atherosclerosis regardless of pre-pregnancy obesity in women with no subsequent…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

March 7, 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
In the Journals

Novel therapy lowered LDL in patients with diabetes, hypercholesterolemia

Cardiology Today, April 2014
ETC-1002, a novel agent in development by Esperion Therapeutics, lowered LDL levels by nearly 43% in patients with type 2 diabetes and…
FDA approvals Perspective

FDA approves Myalept for treatment of lipodystrophy

February 25, 2014
The FDA today approved metreleptin, in combination with diet, for the treatment of complications of leptin deficiency in patients with congenital…

FDA to review heart failure risk associated with saxagliptin

February 11, 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…
FDA News

FDA to review heart failure risk associated with saxagliptin

Cardiology Today, April 2014
The FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released…

CVS plans to stop all tobacco sales

February 6, 2014
CVS Caremark has announced that it will eliminate the sale of cigarettes and other tobacco products in all of its US pharmacies by October.There are…
More Headlines »